Skip to main content
China Resources Double-Crane Pharmaceutical Co.,Ltd. logo

China Resources Double-Crane Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600062 ISIN · CNE000000Q94 LEI · 3003008IFGE1S66ZZA20 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600062

About China Resources Double-Crane Pharmaceutical Co.,Ltd.

https://www.dcpc.com/en/

China Resources Double-Crane Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of a diverse range of pharmaceutical products. The company maintains a significant market presence in several therapeutic areas, including cardiovascular health, endocrinology, pediatrics, and nephrology. It is recognized as a leading provider of large-volume parenteral solutions and chronic disease management medications. Its product portfolio features essential medicines such as antihypertensives, oral hypoglycemic agents, and specialized nutritional supports. Leveraging advanced manufacturing facilities and a robust research and development infrastructure, the company focuses on delivering high-quality healthcare solutions. The organization operates with a commitment to technological innovation and quality control, serving a broad network of medical institutions and healthcare providers.

Recent filings

Filing Released Lang Actions
华润双鹤第十届董事会第二十次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a public announcement of board meeting resolutions (“董事会会议决议公告”), detailing items reviewed and voted on by the Board of Directors, including adoption of a compensation policy and renewal of the audit firm. It is not a full annual or interim report, not a shareholder vote result at a general meeting, nor a proxy statement. It is a miscellaneous regulatory disclosure of board decisions and therefore fits best in the fallback “Regulatory Filings” category (RNS).
2026-05-18 Chinese
华润双鹤关于续聘会计师事务所公告
Regulatory Filings Classification · 70% confidence The document is a corporate announcement regarding the reappointment of the company’s external audit firm (KPMG Huazhen), describing the firm’s background, independence, fees, and the board resolution. It does not contain actual financial statements or an audit report itself, nor does it announce management changes, dividends, or M&A. It is an announcement by the board and thus falls under the general regulatory announcement/fallback category “Regulatory Filings (RNS).”
2026-05-18 Chinese
华润双鹤关于召开2025年度股东会的通知
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a formal notice of the company’s 2025 Annual General Meeting, including date, agenda items, voting procedures and a proxy form for shareholders to appoint representatives and cast votes. It is not the AGM presentation itself nor a results announcement but rather the information and solicitation materials sent to shareholders in advance of the meeting. This matches the definition of a Proxy Solicitation & Information Statement.
2026-05-18 Chinese
华润双鹤关于全资子公司华润赛科药业有限责任公司依折麦布片获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by Huaren Shuanghe Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary receiving a drug registration certificate from the National Medical Products Administration. It does not present financial results, management changes, dividends, or other specific report types. It is a general regulatory/compliance announcement about product approval, which falls under the fallback category for miscellaneous regulatory filings. Therefore, the appropriate classification is 'Regulatory Filings' (RNS).
2026-05-11 Chinese
华润双鹤关于全资子公司安徽双鹤药业有限责任公司钠钾镁钙注射用浓溶液获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 华润双鹤药业股份有限公司 regarding its wholly-owned subsidiary 安徽双鹤药业有限责任公司 receiving a drug registration certificate from the National Medical Products Administration. It details the drug's registration, approval, market status, and impact on the company. The document is short (1580 characters) and serves as a formal public announcement about a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report itself but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-08 Chinese
华润双鹤关于公司2021年限制性股票激励计划首次授予部分第三个解除限售期解锁暨限制性股票上市公告
Share Issue/Capital Change Classification · 90% confidence The document is an official Shanghai Stock Exchange announcement by 华润双鹤药业股份有限公司 regarding the listing and circulation (“上市流通”) of restricted shares under its 2021 restricted stock incentive plan. It details the unlocking (vested release) of 5,247,497 shares and capital structure changes due to this share issuance. This is not a full annual or quarterly report, nor a mere notice of publication. It pertains specifically to a change in share capital tied to employee equity incentives. Under FinancialReports classification, such an equity issuance/capital change announcement falls under “Share Issue/Capital Change” (Code: SHA).
2026-04-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.